Everyone wants to live here. Photo by Kevin Hernandez on Unsplash

Start spreading the news: Houston will eclipse New York City as the 2nd biggest metro area by the year 2100, a new report predicts.

An analysis by moving services site moveBuddha published June 22 says Houston's population could swell to 31.38 million people in the next 77 years.

Based on current population and migration trends, in fact, America’s three biggest metropolitan areas by 2100 will be Dallas-Fort Worth (No. 1), Houston (No. 2), and Austin (No. 3), replacing New York, Los Angeles, and Chicago as the country’s most populous metros, the report predicts.

Dallas-Fort Worth's population is estimated to grow to 33.91 million, and Austin's is projected to jump to 22.29 million.

"The future of America may lie in Texas," the report's author says.

The latest data from the U.S. Census Bureau says Houston-The Woodlands-Sugar Land is currently the No. 5 biggest metro in the country with a population of more than 7.2 million and a 10-year growth rate of about 20 percent.

Houston-The Woodlands-Sugar Land had the second highest numeric increase in population between 2021 and 2022 of any U.S. metro (124,281 residents), following Dallas-Fort Worth-Arlington (170,396 residents), according to the Census Bureau.

There are some risks to continued population booms, including the effects of climate change, moveBuddha points out. While heat will be a major issue, there are much more dangerous possibilities.

"The bigger threat may be more destructive hurricanes from off the Gulf of Mexico," the report's author says. "Hurricane Harvey devastated Houston in 2017, and major storms like that could become more common. A historic flood also nailed the city in 2019. Planning for a future of these climate-induced threats will be critical for Houston."

The study also comes with an obvious caveat: no one is sure what the future looks like in terms of population growth. Academics, scientists, and futurists alike haven't been able to agree on population predictions. Climate change isn't just a risk for Houston, but for the entire world, the report reminds.

"According to one GDP projection through 2099, over three-quarters of U.S. counties will suffer economically because of climate damage," the report says. "That could be from everything from heat-related deaths to sea-level rise to increased natural disasters... But if global warming is held in check, Texas may be America’s haven in 2100. New technologies may help us adapt to extreme weather and heat."

According to the report, the top 10 largest metros and their populations by 2100 will be:

  • No. 1 – Dallas-Fort Worth (33,907,275)
  • No. 2 – Houston (31,384,122)
  • No. 3 – Austin (22,293,980)
  • No. 4 – Phoenix (22,271,212)
  • No. 5 – New York City (20,810,467)
  • No. 6 – Atlanta (18,370,497)
  • No. 7 – Los Angeles (15,502,798)
  • No. 8 – Washington-Arlington, D.C.-Virginia (14,972,830)
  • No. 9 – Orlando (14,172,727)
  • No. 10 – Miami (13,779,843)
These projections were calculated using census data from 2010 and 2020, using annual compound and 10-year population growth rates for U.S. metro areas with over 250,000 people. The study then hypothesized the annual compound growth rates between 2020 and 2100 to find 2100's estimated population numbers for the same cities.The full report and its methodology can be found on movebuddha.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from eaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in the HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”